Goodwin Procter advised gene therapy company Voyager Therapeutics on its recent launch and $45 million Series A financing from Third Rock Ventures. Voyager's adeno-associated virus (AAV) approach to gene therapy has the potential to transform treatment for a wide range of central nervous system (CNS) diseases with one-time therapies.
Voyager Therapeutics’ initial pipeline includes those CNS diseases most in need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia. The company was founded by clinical and scientific leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience. Voyager is based in Cambridge, Mass.
Third Rock Ventures is a healthcare venture firm focused on investing and launching companies that make a difference in people’s lives. Founded in 2007, the firm has raised more than $1.3 billion and invested in 31 companies. Third Rock, based in Boston, Mass., has an extensive track record managing the value creation path to deliver exceptional performance.
The Goodwin team advising Voyager was led by life sciences partner Mitchell Bloom.
More information about Voyager Therapeutics, its launch and financing is available in the company’s press release.